Streetbeat News

EPIX

ESSA Pharma Inc.

https://www.essapharma.com

Industry

Biotechnology

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

Open

1.74

Mkt cap

78M

Volume

29K

High

1.79

P/E Ratio

-2.84

52-wk high

11.67

Low

1.73

Div yield

N/A

52-wk low

1.40

U.S. stocks rose with the Nasdaq surging over 200 points, driven by strong earnings from Amazon, which reported better-than-expected Q3 results. Amazon's shares jumped 7% following the announcement. Other notable stock movements included ChromaDex, Proto Labs, and Interface, which saw significant gains due to positive earnings reports. Conversely, ESSA Pharma, Myriad Genetics, and Lexicon Pharmaceuticals experienced sharp declines due to negative news.

Portfolio Pulse from Avi Kapoor

November 01, 2024 | 4:26 pm

U.S. stocks rose with the Dow Jones gaining over 400 points. The U.S. economy added 12,000 jobs in October, below expectations. ChromaDex, Proto Labs, and Interface saw significant stock price increases due to strong earnings reports, while ESSA Pharma, Elevai Labs, and Lexicon Pharmaceuticals experienced declines.

Portfolio Pulse from Avi Kapoor

November 01, 2024 | 2:43 pm

ESSA Pharma Inc. (NASDAQ:EPIX) has decided to terminate its Phase 2 trial of masofaniten combined with enzalutamide for prostate cancer due to insufficient efficacy. The trial showed a higher PSA90 response rate with Pfizer's Xtandi monotherapy, leading to a futility analysis indicating a low likelihood of meeting the study's primary endpoint. ESSA plans to focus resources elsewhere, ending other studies involving masofaniten. EPIX stock fell 69.80% in premarket trading.

Portfolio Pulse from Vandana Singh

November 01, 2024 | 1:28 pm

Charter Communications shares surged 11.1% in pre-market trading after reporting better-than-expected Q3 EPS and revenues. Other notable pre-market movers include Globalstar, Theriva Biologics, and Atlassian Corporation, which saw significant gains, while ESSA Pharma and Lexicon Pharmaceuticals experienced sharp declines.

Portfolio Pulse from Avi Kapoor

November 01, 2024 | 1:15 pm

Jones Trading analyst Soumit Roy has downgraded ESSA Pharma (NASDAQ:EPIX) from Buy to Hold.